Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs ADMA Biologics, Inc.

AstraZeneca vs. ADMA: A Decade of Cost Efficiency

__timestamp	ADMA Biologics, Inc.	AstraZeneca PLC
Wednesday, January 1, 2014	3742367	5842000000
Thursday, January 1, 2015	4311461	4646000000
Friday, January 1, 2016	6360761	4126000000
Sunday, January 1, 2017	29164321	4318000000
Monday, January 1, 2018	42194635	4936000000
Tuesday, January 1, 2019	39504238	4921000000
Wednesday, January 1, 2020	61291426	5299000000
Friday, January 1, 2021	79769341	12437000000
Saturday, January 1, 2022	118814535	12391000000
Sunday, January 1, 2023	169273000	8040000000
Monday, January 1, 2024		10207000000

Unleashing insights

Cost of Revenue Efficiency: AstraZeneca vs. ADMA Biologics

In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. This analysis compares the cost of revenue efficiency between AstraZeneca PLC and ADMA Biologics, Inc. from 2014 to 2023. Over this period, AstraZeneca consistently demonstrated a robust cost management strategy, with its cost of revenue peaking at approximately $12.4 billion in 2021. In contrast, ADMA Biologics, a smaller player, showed a significant upward trend, with its cost of revenue increasing by over 4,400% from 2014 to 2023, reaching around $169 million. This stark contrast highlights AstraZeneca's scale and efficiency, while ADMA's growth trajectory reflects its expanding operations. As the pharmaceutical landscape continues to shift, these insights provide a glimpse into the strategic financial maneuvers of these two companies.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025